{"id":"iptp-dp","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5776166","moleculeType":null,"molecularWeight":"557.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPTp-DP (Intermittent Preventive Therapy in pregnancy using Dihydroartemisinin-Piperaquine) combines two antimalarial agents: dihydroartemisinin, a fast-acting artemisinin derivative that rapidly reduces parasite burden, and piperaquine, a longer-acting quinoline that provides sustained suppression. This combination is administered as seasonal or monthly doses during pregnancy to prevent malaria parasitemia and its adverse effects on maternal and fetal health.","oneSentence":"IPTp-DP is a dihydroartemisinin-piperaquine combination that prevents malaria infection in pregnant women by killing malaria parasites in the blood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:35:26.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent preventive therapy for malaria in pregnant women"},{"name":"Prevention of malaria in pregnancy in endemic areas"}]},"trialDetails":[{"nctId":"NCT04336189","phase":"PHASE3","title":"Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda","status":"COMPLETED","sponsor":"Grant Dorsey, M.D, Ph.D.","startDate":"2020-12-28","conditions":"Malaria","enrollment":2757},{"nctId":"NCT05294406","phase":"PHASE4","title":"Intermittent Preventive Treatment With Dihydroartemisinin-piperaquine in Papua, Indonesia","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2022-02-07","conditions":"Malaria in Pregnancy","enrollment":2128},{"nctId":"NCT04158713","phase":"PHASE3","title":"Improving PRegnancy Outcomes With PReVEntive Therapy in Africa-2 (IMPROVE-2)","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2019-11-11","conditions":"Pregnancy; HIV; Malaria","enrollment":898},{"nctId":"NCT04189744","phase":"PHASE3","title":"The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-12-15","conditions":"Pregnancy Malaria, Bacterial Vaginoses, Trichomonas Vaginitis","enrollment":5436},{"nctId":"NCT04147546","phase":"PHASE3","title":"Additional Screening With Sensitives RDTs and Malaria","status":"COMPLETED","sponsor":"Institut de Recherche en Sciences de la Sante, Burkina Faso","startDate":"2020-08-31","conditions":"Plasmodium Falciparum Malaria, Malaria Diagnosis","enrollment":340},{"nctId":"NCT03208179","phase":"PHASE3","title":"Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2018-03-29","conditions":"Pregnancy, Malaria in Pregnancy, Malaria","enrollment":4680},{"nctId":"NCT03576313","phase":"PHASE3","title":"Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2018-08-11","conditions":"Malaria","enrollment":4939},{"nctId":"NCT03009526","phase":"PHASE3","title":"Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi","status":"COMPLETED","sponsor":"Kamuzu University of Health Sciences","startDate":"2017-01-17","conditions":"Malaria, Pregnancy","enrollment":602},{"nctId":"NCT04160026","phase":"PHASE4","title":"Acceptability and Feasibility in the Context of the IMPROVE Trial in Kenya","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2019-11-11","conditions":"Malaria in Pregnancy, Adherence, Treatment","enrollment":1600},{"nctId":"NCT01669941","phase":"PHASE4","title":"Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya","status":"COMPLETED","sponsor":"Kenya Medical Research Institute","startDate":"2012-08","conditions":"Pregnancy, Malaria","enrollment":1546}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eurartesim","Duocotexin"],"phase":"marketed","status":"active","brandName":"IPTp-DP","genericName":"IPTp-DP","companyName":"Kenya Medical Research Institute","companyId":"kenya-medical-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IPTp-DP is a dihydroartemisinin-piperaquine combination that prevents malaria infection in pregnant women by killing malaria parasites in the blood. Used for Intermittent preventive therapy for malaria in pregnant women, Prevention of malaria in pregnancy in endemic areas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}